HALO Reports $1.397B Revenue, $868M Royalty, +38% YoY, Guides 2026 Rev $1.710-1.810B, +22-30% YoY, Adj EBITDA $1.125-1.205B, +71-83% YoY, EPS $7.75-8.25, +87-99% YoY
Halozyme Therapeutics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $68.14
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS